Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study

Documenti analoghi

• A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
  di: Wei Zhu, et al.
  Pubblicazione: (2026)
• A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment
  di: Ping Fu, et al.
  Pubblicazione: (2025)
• Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study
  di: Junyu Xu, et al.
  Pubblicazione: (2024)
• Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study
  di: Stein Schalkwijk, et al.
  Pubblicazione: (2025)
• Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
  di: Katharina Erb‐Zohar, et al.
  Pubblicazione: (2024)